European Penny Stocks To Watch In September 2026

The European market has been experiencing a tug-of-war between optimism around AI advancements and concerns over high energy prices, which could lead to further monetary tightening by the European Central Bank. In such a climate, identifying stocks with strong financials becomes crucial for investors seeking opportunities in less conventional areas of the market. Penny stocks, often smaller or newer companies, continue to offer potential value and growth prospects when backed by solid fundamentals.

We're going to check out a few of the best picks from our screener tool.

Ariston Holding (BIT:ARIS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ariston Holding N.V. operates through its subsidiaries to produce and distribute hot water and space heating solutions across the Netherlands, Germany, Italy, Switzerland, and internationally, with a market cap of €1.43 billion.

Operations: The company's revenue is primarily derived from its Thermal Comfort segment at €2.56 billion, followed by Components at €99.9 million and Combustion Technologies at €104.7 million.

Market Cap: €1.43B

Ariston Holding N.V. has shown a mixed financial performance, with recent half-year revenues of €1.37 billion, up from €1.30 billion the previous year, yet net income dropped to €35.5 million from €58.7 million. While the company benefits from experienced leadership and stable weekly volatility, its return on equity is low at 7.1%. The net debt to equity ratio is high at 46.3%, though interest payments are well covered by EBIT at 5.2x coverage. Despite challenges in profit growth historically declining by 12% annually over five years, recent earnings have improved by 17%.

• Take a closer look at Ariston Holding's potential here in our financial health report.
• Gain insights into Ariston Holding's future direction by reviewing our growth report.

Nightingale Health Oyj (HLSE:HEALTH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nightingale Health Oyj is a health technology company that provides advanced health checks for detecting disease risks across Finland, the United Kingdom, the rest of Europe, the United States, and internationally with a market cap of €56.62 million.

Operations: The company's revenue is primarily generated from its Medical Labs & Research segment, amounting to €5.50 million.

Market Cap: €56.62M

Nightingale Health Oyj's recent strategic partnerships, including agreements with Archipelago Health and Coronaria Kuntoutuspalvelut Oy, aim to expand its health check services across various regions. Despite a net loss of €18.47 million for the year ending June 2026, the company reported revenues of €5.50 million from its Medical Labs & Research segment. The firm remains unprofitable with a negative return on equity yet benefits from being debt-free and having sufficient cash runway for over three years. Revenue is projected to grow annually by 30.4%, but profitability is not expected in the near term.

• Navigate through the intricacies of Nightingale Health Oyj with our comprehensive balance sheet health report here.
• Evaluate Nightingale Health Oyj's prospects by accessing our earnings growth report.

Sprint Bioscience (OM:SPRINT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Sprint Bioscience AB (publ) is a Swedish pharmaceutical company focused on developing drug candidates for cancer treatment, with a market cap of SEK329.21 million.

Operations: Sprint Bioscience has not reported any specific revenue segments.

Market Cap: SEK329.21M

Sprint Bioscience, a Swedish pharmaceutical company, has recently become profitable despite its pre-revenue status with negligible revenue of SEK 0.059 million for the first half of 2026. The firm boasts an experienced board and management team while benefiting from being debt-free. Its strategic alliance with Lilly TuneLab is set to enhance its drug discovery capabilities through AI-driven models, potentially accelerating its preclinical programs. Despite reporting a net loss of SEK 29.1 million for the same period, Sprint's strong return on equity and high-quality earnings provide some positive indicators amidst financial challenges.

• Click here and access our complete financial health analysis report to understand the dynamics of Sprint Bioscience.
• Review our growth performance report to gain insights into Sprint Bioscience's future.

Turning Ideas Into Actions

• Gain an insight into the universe of 307 European Penny Stocks by clicking here.
• Ready For A Different Approach? We've found 6 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com